AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01730560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: The computer-based training task consists of a novel ramp-step search paradigm with a stimulus traversing the screen from left to right or right to left. Subjects are asked to pursue the stimulus (ramp phase) and then saccade to find its location when it suddenly jumps (step phase). The stimulus is an open spinning circle. At the end of each movement, the gap can be located at the top or at the bottom, and patients are asked to indicate this location by pushing the response button as quickly as possible.~The starting point will alternate between left and right. The training task includes 3 sessions with 100 movements each. Reaction Times and errors will be monitored online to ensure that the patient performs the task correctly.~Each treatment phase has the same pattern:~* two visits in pre-tests evaluation (V1 and V2),~* one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),~* two visits after treatment (V4 at one week and V5 at one month).
Study NCT01730560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Placebo treatment using the same computer-based training task, but including only the ramp phase.~Each treatment phase has the same pattern:~* two visits in pre-tests evaluation (V1 and V2),~* one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),~* two visits after treatment (V4 at one week and V5 at one month).
Study NCT00518882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 1.8 mg once daily for s.c. (under the skin) injection.
Study NCT00518882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide
Description: 10 mcg twice daily for s.c. (under the skin) injection.
Study NCT01128582 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rozerem (ramelteon)
Description: dosage= take 1 tablet(8 MG) 20 min. before bedtime
Study NCT01128582 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Comparing the effect of Rozerem vs. placebo on GERD symptomatology.
Study NCT01581775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex Sodium
Description: Divalproex Sodium ER Tablets, 500 mg
Study NCT01581775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium
Description: Divalproex Sodium ER Tablets, 500 mg
Study NCT04010695 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SD Biosensor G6PD Analyzer
Description: The SD Biosensor G6PD Analyzer is designed to measure the quantitative determination of total hemoglobin concentration and G6PD enzymatic activity in fresh human whole blood specimens based on reflectometry assays in a point-of-care setting. The test is intended to aid in the identification of people with G6PD deficiency. The test is currently not licensed for use in the US and is considered an investigational product.
Study NCT00405951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate 250 ml
Study NCT00405951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT02925195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: cholecalciferol (vitamin D3) 2000 IU capsules daily
Study NCT02925195 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01050569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: 21 mg
Study NCT01050569 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VLNC Cigarette
Description: Cigarette where the tobacco contains \<0.1 mg of nicotine yield.
Study NCT01050569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VLNC Cigarette Plus Nicotine Patch
Description: 21 mg nicotine patch plus use of cigarette with tobacco containing \<0.1 mg nicotine yield.
Study NCT02118077 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT
Study NCT00810680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: Tab. Valproic acid will be started at a dose of 10 mg per kg per day in two or three divided doses. If well tolerated the dose will be increased to a maximum of 20 mg per kg per day and continued for a period of 3 months. The drug will be continued for another 3 months for a maximum of 6 months in responding patients. The drug will be stopped in all those who develop intolerable side effects or develop disease progression during therapy.
Study NCT03587168 — intervention group
Intervention type: OTHER
Intervention: the timed 360° turn test
Description: Turning ability is assessed by using the timed 360° turn test.
Study NCT03587168 — intervention group
Intervention type: OTHER
Intervention: Berg Balance Scale
Description: Functional balance is assessed by using the Berg Balance Scale.
Study NCT03587168 — intervention group
Intervention type: OTHER
Intervention: Four Square Step Test
Description: The Four Square Step Test measures dynamic balance.
Study NCT03587168 — intervention group
Intervention type: OTHER
Intervention: Functional Reach Test
Description: The Functional Reach Test assesses limits of stability.
Study NCT03587168 — intervention group
Intervention type: OTHER
Intervention: Trunk Impairment Scale
Description: Trunk performance is assessed by using the trunk impairment scale.
Study NCT03587168 — intervention group
Intervention type: OTHER
Intervention: Timed Up and Go Test
Description: Functional mobility is assessed by using the timed up and go test.
Study NCT03587168 — intervention group
Intervention type: OTHER
Intervention: Hoehn and Yahr Scale
Description: Disease stage is assessed by the Hoehn and Yahr Scale.
Study NCT03587168 — intervention group
Intervention type: OTHER
Intervention: Unified Parkinson's Disease Rating Scale
Description: The Unified Parkinson's Disease Rating Scale assesses disease severity.
Study NCT00571818 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral glucose tolerance test
Description: test done over 2 hours
Study NCT00571818 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IV Glucose Tolerance Test
Description: Done over 4 hours
Study NCT01491399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™
Description: Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
Study NCT01491399 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™
Description: Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
Study NCT04220632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: at the protocol-defined dose administered orally once daily (QD) plus corticosteroids.
Study NCT04220632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
Study NCT04220632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
Study NCT01818050 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Liver Function Tests
Description: LFTs will be checked periodically after Wing stent placement to evaluate stent patency
Study NCT03215394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Training Program
Description: The attention training involves 8 visits over 4 weeks with pre/post data collection before and after the training, and a follow-up 6 months later. Pre/post data collection involves the ESCS and a Laboratory Temperament Assessment Battery (LabTAB), and a series of on-screen assessment tasks that measure cognitive control, distraction tolerance, sustained attention, habituation, gap-overlap, disengagement, and attention to static images. Training runs from Wk 2-5 with 2 visits per week and is completed in home with the child sitting on the parents lap in front of a monitor. The parent and child are inside a tent to reduce environmental stimuli. The research trainer is outside the tent running the program from a laptop. The program consists of a battery of 9 gaze-contingent training tasks using custom MATLAB scripts. The animated tasks are designed to engage the child and present as developmentally appropriate games. At each visit 6 of the 9 tasks will run for a total of 4min each(24min).
Study NCT03215394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social ABCs
Description: The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
Study NCT03215394 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Social ABCs
Description: The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
Study NCT03215394 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment As Usual
Description: The Treatment as Usual group acts as a pre-existing convenience sample, consisting of families currently enrolled in a different approved research study run by the same group of investigators. Children in this group have comparable clinical concerns for ASD, and complete the same standardized measures (ADOS, MSEL, ESCS, AOSI) as the Baseline assessment in this RCT, but will not receive Social ABCs or the Attention Training Program. They are able to access any programs or interventions available to them in the general community. This is tracked on a Services Log form, included as part of that study's protocol. Families in this group will have consented to their child's data being shared across studies in this research group.
Study NCT03215394 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Attention Training
Description: The sham attention condition will use identical hardware, administered by the same research staff for the same frequency and duration as the attention training program (8 visits over 4 weeks including pre/post data collection). In this condition, infants will be exposed to non-gaze contingent visual stimuli that offer no adaptive difficulty levels (ie. clips of age appropriate television shows). Placebo stimuli will be presented until toddlers become fidgety or distressed.
Study NCT01897181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing aids
Description: Using hearing aids for 12 months
Study NCT01165593 — intervention group
Intervention type: OTHER
Intervention: There is no intervention that is a part of this study.
Description: There is no intervention that is a part of this study. Imaging data is gathered as part of normal care.
Study NCT01426607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMO
Study NCT01426607 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: AMO
Study NCT03656120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2mg group
Description: Thienorphine hydrochloride dose was set as 0.2mg per day,last for 12 weeks.
Study NCT03656120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5mg group
Description: Thienorphine hydrochloride dose was set as 0.2mg per day for the first week and increased to 0.5mg per day from the second week, last for 11 weeks.
Study NCT03656120 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo control group
Description: Participants only take placebos for 12 weeks during the research.
Study NCT03081286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liposuction
Description: Liposuction is performed on the abdomen or thighs as determined before randomization by the surgeon.
Study NCT03081286 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Liposuction
Description: Liposuction is performed on the abdomen or thighs as determined before randomization by the surgeon.
Study NCT03081286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat graft
Description: The harvested lipoaspirate is injected at the site of pain.
Study NCT03081286 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham graft (saline injection)
Description: Saline will be injected at the site of pain instead of fat
Study NCT03280017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: intravenous ketamine 0.2 mg/kg/hr (concentration 1 mg/ml)
Study NCT03280017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: normal saline infusion
Study NCT02762006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a programmed cell death ligand-1 monoclonal antibody which has demonstrated anti-tumor efficacy renal cell carcinoma and other malignancies via activation of the immune system.
Study NCT02762006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab is a CTLA-4 monoclonal antibody.
Study NCT00855465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: BAY63-2521: 1 mg tid - 2,5 mg tid orally for 16 weeks.
Study NCT00855465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo tid orally for 16 weeks
Study NCT03030248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin Oral Capsule
Description: We have chosen oral vancomycin capsules as it is currently a standard of care for Clostridium difficile infections, is poorly absorbed by the intestines, and is easier to blind compared to oral vancomycin solution.
Study NCT03030248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: A capsule containing gelatin, polyethylene glycol, titanium dioxide, iron oxide, and FD\&C blue No. 2. Contains the inactive ingredients of the vancomycin oral capsule, as mixed by the Froedtert Health Research Pharmacy.
Study NCT04435002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: Acupressure technics applied to (Liv- 4 , Ht-7 Bilateral, Liv-3 Bilateral, Anmian Bilateral, Yin-Tang unilateral ve Sp-6 Bilateral)
Study NCT03432988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing Solution-Focused
Description: Two two-hour training modules were designed. In each module, participants watched videos that illustrated solution-focused communication on fluid adherence, and practiced the skills in role-plays. Solution-focused communication on IDWG. In the case of IDWG improvement, nurses were trained to congratulate the patient and then to explore in detail, from a stance of curiosity, how s/he had accomplished the weight reduction. Nurses were trained to invite patients to share specific behavioral details, to describe their own behavior from the perspective of significant family members and also to compliment patients on their accomplishments and to invite them to keep track of anything else they might find useful to control fluid intake over the next days.
Study NCT01713179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol hydrochloride (Mucopect®, 60 mg, Boehringer Ingelheim)
Study NCT01401387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Timing of start treatment with pancreatic enzymes
Description: Patients who are randomised to standard treatment will start taking pancreatic enzymes only if they develop steatorrhea-related symptoms in combination with at least a 10% decrease in body weight (index weight at the time of randomisation).
Study NCT01401387 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Timing of start treatment with pancreatic enzymes
Description: Patients who are allocated to the anticipative group will start enzyme suppletion immediately and receive dietary consultation after randomization, regardless of symptoms.
Study NCT02660645 — intervention group
Intervention type: DRUG
Intervention: Hexaminolevulinate hydrochloride (HCL)
Description: Instillation in bladder
Study NCT02660645 — intervention group
Intervention type: DEVICE
Intervention: Karl Storz D-Light C Photodynamic Diagnostic (PDD) system
Description: Cystoscopy procedure
Study NCT01610479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-114 + S-1
Study NCT02817724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BENECA System
Description: BENECA System is a mobile application whit aims to recover a healthy lifestyle in breast cancer survivors (in terms of energy balance: physical activity and dietary).
Study NCT02537379 — intervention group
Intervention type: DRUG
Intervention: SOF
Description: SOF 400 mg tablets administered orally once daily
Study NCT04010695 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Pointe Scientific Test Kit
Description: The Pointe Scientific test kit will serve as the reference assay to assess G6PD activity. Its intended use is for the quantitative, kinetic determination of G6PD in blood at 340 nm.
Study NCT04010695 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HemoCue System
Description: The HemoCue hemoglobin (Hb) 201+ system is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 201+ Analyzer, and specially designed microcuvettes, the HemoCue Hb 201+Microcuvettes.
Study NCT02817724 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BENECA System
Description: BENECA System is a mobile application whit aims to recover a healthy lifestyle in breast cancer survivors (in terms of energy balance: physical activity and dietary).
Study NCT02817724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised-occupational therapy program
Description: It is a comprehensive program that covers most of the physical, cognitive and emotional needs of these patients after oncology treatment from occupational therapy perspective.
Study NCT02537379 — intervention group
Intervention type: DRUG
Intervention: COPE
Description: COPE tablets administered orally in a divided daily weight-based dose according to the package insert for the approved Copegus® labeling in Japan (\< 60 kg = 600 mg , > 60 kg to ≤ 80 kg = 800 mg, and > 80 kg = 1000 mg)
Study NCT00504335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIO 300 Capsules
Study NCT01505881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate low dose
Description: active treatment (low)
Study NCT01505881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin 5mg
Description: comparator warfarin
Study NCT01505881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate intermediate dose
Description: active treatment (medium)
Study NCT01505881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin 1mg
Description: comparator warfarin
Study NCT01505881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate high dose
Description: active treatment (high)
Study NCT01505881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin 3mg
Description: comparator warfarin
Study NCT03121586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin
Description: Pimavanserin 10 mg, tablet, taken as one 10 mg tablets, once daily by mouth, OR Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
Study NCT02599818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NavSTAR
Description: Participants in the NavSTAR program will work with a team of case workers who will provide motivational intervention and proactive barrier resolution services using patient navigation
Study NCT00845832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: iv on days 1 and 15 (Parts 1 and 2)
Study NCT00845832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 0.5g iv on days 1 and 15 (Parts 1 and 2)
Study NCT00845832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 2mg/kg-8mg/kg iv in Part 1 and selected dose in Part 2, on weeks 4, 8 and 12---Arm 1\\n8mg/kg iv on weeks 4,8 and 12 (Parts 1 and 2)--- Arm 2